

**TRADEMARK ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	Release of Security Interest Recorded at Reel/Frame 4080/600

**CONVEYING PARTY DATA**

Name	Formerly	Execution Date	Entity Type
JPMorgan Chase Bank, N.A., as Administrative Agent		11/30/2010	National Banking Association: UNITED STATES

**RECEIVING PARTY DATA**

<b>Name:</b>	Endo Pharmaceuticals Solutions Inc.
<b>Street Address:</b>	100 ENDO BOULEVARD LEGAL DEPARTMENT
<b>City:</b>	CHADDS FORD
<b>State/Country:</b>	PENNSYLVANIA
<b>Postal Code:</b>	19317
<b>Entity Type:</b>	CORPORATION: DELAWARE

**PROPERTY NUMBERS Total: 8**

Property Type	Number	Word Mark
Registration Number:	0589157	DELATESTRYL
Registration Number:	2337316	HYDRON
Registration Number:	2547623	HYDRON
Registration Number:	3040977	I INDEVUS PHARMACEUTICALS, INC.
Registration Number:	3007230	INDEVUS PHARMACEUTICALS
Registration Number:	2875279	INDEVUS PHARMACEUTICALS
Registration Number:	1638851	SUPPRELIN
Registration Number:	2929415	VANTAS

**CORRESPONDENCE DATA**

Fax Number: (214)981-3400  
*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*  
 Phone: 214-981-3483  
 Email: dclark@sidley.com  
 Correspondent Name: Dusan Clark, Esq.

**900177877**

**TRADEMARK  
 REEL: 004424 FRAME: 0791**

**CH \$215.00 0589157**

Address Line 1: Sidley Austin LLP  
Address Line 2: 717 N. Harwood St., Suite 3400  
Address Line 4: Dallas, TEXAS 75201

ATTORNEY DOCKET NUMBER: 36084-36730

NAME OF SUBMITTER: Dusan Clark

Signature: /Dusan Clark/

Date: 12/03/2010

**Total Attachments: 3**

source=Executed EPSI Trademark Release#page1.tif  
source=Executed EPSI Trademark Release#page2.tif  
source=Executed EPSI Trademark Release#page3.tif

**RELEASE OF TRADEMARK SECURITY INTEREST**

THIS RELEASE OF TRADEMARK SECURITY INTEREST is made effective as of November 30, 2010, by and from JPMORGAN CHASE BANK, N.A., for itself and as Administrative Agent for the Secured Parties (the "Administrative Agent") to ENDO PHARMACEUTICALS SOLUTIONS INC., a Delaware corporation (the "Grantor") as follows:

WHEREAS, on October 16, 2009, the Grantor and the Administrative Agent entered into a Pledge and Security Agreement (the "Security Agreement") and a Confirmatory Grant of Security Interest in United States Trademarks (the "Confirmatory Grant");

WHEREAS, pursuant to the Security Agreement and the Confirmatory Grant, the Grantor granted to the Administrative Agent on behalf of the Secured Parties, among other collateral, a continuing security interest in all of (1) the Grantor's right, title and interest, its trademarks (including service marks), trade names, trade styles, trade dress and the registrations and applications for registration thereof, including the Trademarks and the United States Trademarks listed on the attached Schedule A (the "Marks"), then owned or from time to time after the date thereof owned or acquired by the Grantor and the goodwill of the business symbolized by the foregoing; (2) all licenses of the foregoing, whether as licensee or licensor; (3) all renewals of the foregoing; (4) all income, royalties, damages, and payments now or hereafter due or payable with respect thereto, including, without limitation, damages, claims, and payments for past and future infringements thereof; and (5) all rights to sue for past, present, and future infringements of the foregoing, including the right to settle suits involving claims and demands for royalties owing;

WHEREAS, the Confirmatory Grant was recorded in the United States Patent & Trademark Office on October 19, 2009 at reel/frame 004080/00600; and


WHEREAS, the Administrative Agent wishes to release its security interest in the all of the foregoing;

NOW THEREFORE, the Administrative Agent hereby releases any security interest it may have in Grantor's trademarks (including service marks), trade names, trade styles, trade dress and the registrations and applications for registration thereof, including the Trademarks and the Marks, now owned or from time to time after the date hereof owned or acquired by the Grantor and the goodwill of the business symbolized by the foregoing; (2) all licenses of the foregoing, whether as licensee or licensor; (3) all renewals of the foregoing; (4) all income, royalties, damages, and payments now or hereafter due or payable with respect thereto, including, without limitation, damages, claims, and payments for past and future infringements thereof; and (5) all rights to sue for past, present, and future infringements of the foregoing, including the right to settle suits involving claims and demands for royalties owing, and retransfers and reassigns any and all right, title and interest it may have in any of the foregoing without recourse to Grantor.

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, the Administrative Agent has caused this Release to be executed by its duly authorized officer.

JPMORGAN CHASE BANK, N.A.

By: 

Name: Deborah R. Winkler

Title: Vice President

**Schedule A**  
**Security Interests in Trademarks recorded at**  
**Reel 004080 Frame 00600**

<b>Trademark</b>	<b>App. No.</b>	<b>App.Date</b>	<b>Reg. No.</b>	<b>Reg.Date</b>
AVEED	77/736,575	5/14/2009		
DELATESTRYL	71/649,803	7/3/1953	0,589,157	4/27/1954
HYDRON	75/482,236	5/8/1998	2,337,316	4/4/2000
HYDRON	75/481,957	5/8/1998	2,547,623	3/12/2002
I INDEVUS PHARMACEUTICALS & Design	78/511,215	11/4/2004	3,040,977	1/10/2006
INDEVUS PHARMACEUTICALS	78/285,011	8/8/2003	3,007,230	10/18/2005
INDEVUS PHARMACEUTICALS	76/355,179	1/4/2002	2,875,279	8/17/2004
SUPPRELIN	74/004,595	11/22/1989	1,638,851	3/26/1991
VALSTAR	77/332,945	11/19/2007		
VANTAS	76/522,929	6/17/2003	2,929,415	3/1/2005

Applications were not recorded at Reel/Frame 004080/00600 and will not be included in the Release filing with the USPTO.